Русский
A comparative characteristics of treatment results of patiens with benign prostatic hyperplasia in combination with hypogonadism
DOI: https://dx.doi.org/10.18565/urology.2019.4.58-61
A.A. Kamalov, R.P. Vasilevskiy, D.A. Okhobotov, E.A. Neplokhov
1) Moscow Research and Education Center of the Lomonosov Moscow State University (Director – academician, MD Kamalov A.A.), Moscow, Russia; 2) Lomonosov Moscow State University, Faculty of Fundamental Medicine, Urology and Andrology Department (rector – academician, MD Kamalov A.A.), Moscow, Russia; 3) Municipal Polyclinic №134 (Chief – Borisova O.I.), Moscow, Russia; 4) Tomsk OGAUZ I.D. Evtushenko Regional Perinatal Center (Chief – Ph.D. Stepanov I.A.), Tomsk, Russia
Aim: to compare the efficiency of monotherapy with α-blockers vs combined therapy (α-blockers in combination with Androgel) in patients with BPH and hypogonadism.
Materials and methods: a total of 60 men with BPH and hypogonadism, who were randomly selected from outpatient department were included in the study. All patients were divided into 2 groups (n=30). In Group 1 patients received silodosin, while in Group 2 men were prescribed to silodosin plus Androgel 1% topically. The duration of therapy was 6 months. The results of treatment were evaluated during baseline assessment and further visits every 2 months after starting therapy (total 4 time points).
Results: according to the ICEF-5 questionnaire, in the Group 2 an improvement in sexual function domain score (from 6.3 to 26.8 points) was shown. In addition, in combination group there were significant changes in PSA level (from 2.25 to 1.8 ng/ml), prostate volume (from 55.1 to 61.3 cm3), residual urine volume (from 72 to 19 ml), urine flow rate (from 13.34 to 21.1 ml/s), waist circumference (from 116 to 103.2 cm) and body mass index (from 35.4 to 27.2 kg/m2), while in monotherapy group none of these indicators significantly improved.
Conclusions: the use of topical hormone replacement therapy in combination with α-blockers in patients with BPH and concomitant hypogonadism is justified and effective in comparison with monotherapy with α-blockers.
Materials and methods: a total of 60 men with BPH and hypogonadism, who were randomly selected from outpatient department were included in the study. All patients were divided into 2 groups (n=30). In Group 1 patients received silodosin, while in Group 2 men were prescribed to silodosin plus Androgel 1% topically. The duration of therapy was 6 months. The results of treatment were evaluated during baseline assessment and further visits every 2 months after starting therapy (total 4 time points).
Results: according to the ICEF-5 questionnaire, in the Group 2 an improvement in sexual function domain score (from 6.3 to 26.8 points) was shown. In addition, in combination group there were significant changes in PSA level (from 2.25 to 1.8 ng/ml), prostate volume (from 55.1 to 61.3 cm3), residual urine volume (from 72 to 19 ml), urine flow rate (from 13.34 to 21.1 ml/s), waist circumference (from 116 to 103.2 cm) and body mass index (from 35.4 to 27.2 kg/m2), while in monotherapy group none of these indicators significantly improved.
Conclusions: the use of topical hormone replacement therapy in combination with α-blockers in patients with BPH and concomitant hypogonadism is justified and effective in comparison with monotherapy with α-blockers.
About the Autors
Corresponding author: R.P. Vasilevskiy – urologist, Head of the Department of Urology of MP №134, Moscow, Russia; e-mail: urolog-rv@yandex.ru
Similar Articles
